Spots Global Cancer Trial Database for A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Official Title: A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Study ID: NCT00664170
Conditions
Study Description
Brief Summary: The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
UCSD Moores Cancer Center, La Jolla, California, United States
Signal Point Hematology/Oncology Inc., Middletown, Ohio, United States
Hospital Universitario Austral, Buenos Aires, Provincia de Buenos Aires, Argentina
Centro Oncologico de Rosario, Rosario, Santa Fe, Argentina
Hospital Regional de Concepcion, Concepcion, Tucuman, Argentina
Marcelo T de Alvear, Buenos Aires, , Argentina
Centro Oncologico de Integracion Regional, Mendoza, , Argentina
Hospital Privado Santa Clara de Asis, Salta, , Argentina
Isis Centro Especializado, Santa Fe, , Argentina
Centro Medico San Roque, Tucuman, , Argentina
Tallinn Cancer Clinic, Tallinn, , Estonia
Tartu University Hospital, Clinic of Hematology and Oncology, Tartu, , Estonia
Contact Details
Name: Jeff Stewart, MBA
Affiliation: Mast Therapeutics, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
